Oreofe O Odejide1, Angel M Cronin2, Nolan B Condron2, Sean A Fletcher2, Craig C Earle2, James A Tulsky2, Gregory A Abel2. 1. Oreofe O. Odejide, Angel M. Cronin, Nolan B. Condron, Sean A. Fletcher, James A. Tulsky, Gregory A. Abel, Dana-Farber Cancer Institute; James A. Tulsky, Brigham and Women's Hospital, Boston, MA; and Craig C. Earle, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. oreofe_odejide@dfci.harvard.edu. 2. Oreofe O. Odejide, Angel M. Cronin, Nolan B. Condron, Sean A. Fletcher, James A. Tulsky, Gregory A. Abel, Dana-Farber Cancer Institute; James A. Tulsky, Brigham and Women's Hospital, Boston, MA; and Craig C. Earle, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Abstract
PURPOSE: Patients with blood cancers have been shown to receive suboptimal care at the end of life (EOL) when assessed with standard oncology quality measures (eg, no chemotherapy ≤ 14 days before death). As they were developed primarily for solid tumors, it is unclear if these measures are appropriate for patients with hematologic malignancies. Moreover, barriers to high-quality EOL care for this specific patient population are largely unknown. METHODS: In 2015, we asked a national cohort of hematologic oncologists about the acceptability of eight standard EOL quality measures. Building on prior qualitative work, we prespecified that measures achieving agreement among at least 55% of respondents would be considered acceptable. We also explored perspectives regarding barriers to quality EOL care. RESULTS: We received 349 surveys (response rate = 57.3%). Six of the standard measures met the threshold of acceptability, and four were acceptable to > 75% of respondents: hospice admission > 7 days before death, no chemotherapy ≤ 14 days before death, no intubation in the last 30 days of life, and no cardiopulmonary resuscitation in the last 30 days of life. The highest-ranked barriers to quality EOL care reported were "unrealistic patient expectations" (97.3%), "clinician concern about taking away hope" (71.3%), and "unrealistic clinician expectations" (59.0%). CONCLUSION: In this large national cohort of hematologic oncologists, standard EOL quality measures were highly acceptable. The top barrier to quality EOL care reported was unrealistic patient expectations, which may be best addressed with more timely and effective advance care discussions.
PURPOSE:Patients with blood cancers have been shown to receive suboptimal care at the end of life (EOL) when assessed with standard oncology quality measures (eg, no chemotherapy ≤ 14 days before death). As they were developed primarily for solid tumors, it is unclear if these measures are appropriate for patients with hematologic malignancies. Moreover, barriers to high-quality EOL care for this specific patient population are largely unknown. METHODS: In 2015, we asked a national cohort of hematologic oncologists about the acceptability of eight standard EOL quality measures. Building on prior qualitative work, we prespecified that measures achieving agreement among at least 55% of respondents would be considered acceptable. We also explored perspectives regarding barriers to quality EOL care. RESULTS: We received 349 surveys (response rate = 57.3%). Six of the standard measures met the threshold of acceptability, and four were acceptable to > 75% of respondents: hospice admission > 7 days before death, no chemotherapy ≤ 14 days before death, no intubation in the last 30 days of life, and no cardiopulmonary resuscitation in the last 30 days of life. The highest-ranked barriers to quality EOL care reported were "unrealistic patient expectations" (97.3%), "clinician concern about taking away hope" (71.3%), and "unrealistic clinician expectations" (59.0%). CONCLUSION: In this large national cohort of hematologic oncologists, standard EOL quality measures were highly acceptable. The top barrier to quality EOL care reported was unrealistic patient expectations, which may be best addressed with more timely and effective advance care discussions.
Authors: Nneka N Ufere; John Donlan; Lauren Waldman; Arpan Patel; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph Greer; Jennifer Temel; Raymond T Chung; Areej El-Jawahri Journal: Liver Transpl Date: 2019-05-03 Impact factor: 5.799
Authors: Nneka N Ufere; John Donlan; Lauren Waldman; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph A Greer; Jennifer S Temel; Raymond T Chung; Areej El-Jawahri Journal: Clin Gastroenterol Hepatol Date: 2019-03-15 Impact factor: 11.382
Authors: Rong Wang; Amer M Zeidan; Stephanie Halene; Xiao Xu; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Cary P Gross; Steven D Gore; Xiaomei Ma Journal: J Clin Oncol Date: 2017-08-07 Impact factor: 44.544